Richwood Investment Advisors LLC bought a new position in Johnson & Johnson (NYSE: JNJ – Get Rating) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 3,883 shares of the company stock, valued at approximately $ 664,000.
A number of other hedge funds have also bought and sold shares of JNJ. Steward Financial Group LLC acquired a new position in Johnson & Johnson during the 4th quarter valued at $ 34,000. Jackson Wealth Management LLC raised its stake in Johnson & Johnson by 1.7% during the 3rd quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company stock valued at $ 40,000 after purchasing an additional 277 shares during the last quarter. Iron Horse Wealth Management LLC raised its stake in shares of Johnson & Johnson by 29.9% in the 4th quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company stock valued at $ 45,000 after buying an additional 61 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its stake in shares of Johnson & Johnson by 290.7% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company stock valued at $ 47,000 after buying an additional 218 shares in the last quarter. Finally, Gibson Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $ 49,000. 68.78% of the stock is owned by institutional investors.
JNJ has been the topic of several analyst reports. Sanford C. Bernstein lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and upped their target price for the stock from $ 180.00 to $ 183.00 in a report on Wednesday, March 16th. Raymond James upped their target price on shares of Johnson & Johnson from $ 195.00 to $ 196.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Bank of America started coverage on shares of Johnson & Johnson in a report on Wednesday, March 2nd. They issued a “neutral” rating on the stock. The Goldman Sachs Group increased their price target on shares of Johnson & Johnson from $ 163.00 to $ 181.00 and gave the stock a “neutral” rating in a report on Tuesday, April 12th. Finally, Morgan Stanley decreased their price objective on shares of Johnson & Johnson from $ 175.00 to $ 173.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 6th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $ 190.50.
NYSE JNJ opened at $ 169.99 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. Johnson & Johnson has a 12-month low of $ 155.72 and a 12-month high of $ 186.69. The company has a market capitalization of $ 447.31 billion, a PE ratio of 22.91, a price-to-earnings-growth ratio of 3.41 and a beta of 0.66. The firm’s 50 day moving average is $ 178.59 and its 200-day moving average is $ 172.62.
Johnson & Johnson (NYSE: JNJ – Get Rating) last released its earnings results on Tuesday, April 19th. The company reported $ 2.67 earnings per share for the quarter, beating the consensus estimate of $ 2.60 by $ 0.07. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The business had revenue of $ 23.43 billion during the quarter, compared to analysts’ expectations of $ 23.62 billion. During the same period last year, the business earned $ 2.59 earnings per share. The firm’s revenue was up 5.0% on a year-over-year basis. As a group, sell-side analysts expect that Johnson & Johnson will post 10.23 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th were issued a dividend of $ 1.13 per share. The ex-dividend date of this dividend was Monday, May 23rd. This represents a $ 4.52 dividend on an annualized basis and a dividend yield of 2.66%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $ 1.06. Johnson & Johnson’s dividend payout ratio (DPR) is currently 60.92%.
In related news, insider William Hait sold 29,699 shares of the business’s stock in a transaction dated Thursday, April 21st. The stock was sold at an average price of $ 183.58, for a total value of $ 5,452,142.42. Following the completion of the transaction, the insider now owns 80,236 shares of the company stock, valued at $ 14,729,724.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $ 173.00, for a total value of $ 6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company stock, valued at approximately $ 12,336,803. The disclosure for this sale can be found here. Insiders have sold 78,161 shares of company stock valued at $ 13,895,302 in the last three months. Insiders own 0.35% of the company stock.
Johnson & Johnson Company Profile: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
Recommended Stories:
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE: JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.
.